ESC Working Group Cellular Biology of the Heart: Position Paper: Improving the Preclinical Assessment of Novel Cardioprotective Therapies

Overview

Journal Cardiovasc Res

Specialty Cardiology & Vascular Diseases

Date 2014 Oct 26

PMID 25344369

Citations 76

Authors

Sandrine Lecour

Hans E Botker

Gianluigi Condorelli

Sean M Davidson

David Garcia-Dorado

Felix B Engel

Peter Ferdinandy

Gerd Heusch

Rosalinda Madonna

Michel Ovize

Marisol Ruiz-Meana

Rainer Schulz

Joost P G Sluijter

Linda W van Laake

Derek M Yellon

Derek J Hausenloy

Affiliations

Soon will be listed here.

Abstract

Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide. As a result, novel therapies are still needed to protect the heart from the detrimental effects of acute ischaemia-reperfusion injury, in order to improve clinical outcomes in IHD patients. In this regard, although a large number of novel cardioprotective therapies discovered in the research laboratory have been investigated in the clinical setting, only a few of these have been demonstrated to improve clinical outcomes. One potential reason for this lack of success may have been the failure to thoroughly assess the cardioprotective efficacy of these novel therapies in suitably designed preclinical experimental animal models. Therefore, the aim of this Position Paper by the European Society of Cardiology Working Group Cellular Biology of the Heart is to provide recommendations for improving the preclinical assessment of novel cardioprotective therapies discovered in the research laboratory, with the aim of increasing the likelihood of success in translating these new treatments into improved clinical outcomes.

Citing Articles

Swine Model of Myocardial Infarction Induced by Ischemia-Reperfusion and Embolization.

Mazurek R, Bikou O, Ishikawa K Methods Mol Biol. 2024; 2803:189-203.

PMID: 38676894 DOI: 10.1007/978-1-0716-3846-0_14.

Identification of a mechanism promoting mitochondrial sterol accumulation during myocardial ischemia-reperfusion: role of TSPO and STAR.

Brehat J, Leick S, Musman J, Su J, Eychenne N, Giton F Basic Res Cardiol. 2024; 119(3):481-503.

PMID: 38517482 DOI: 10.1007/s00395-024-01043-3.

Simultaneous assessment of mechanical and electrical function in Langendorff-perfused mouse hearts.

Louradour J, Ottersberg R, Segiser A, Olejnik A, Martinez-Salazar B, Siegrist M Front Cardiovasc Med. 2023; 10:1293032.

PMID: 38028448 PMC: 10663365. DOI: 10.3389/fcvm.2023.1293032.

Assessment of Squalene-Adenosine Nanoparticles in Two Rodent Models of Cardiac Ischemia-Reperfusion.

Brusini R, Tran N, Cailleau C, Domergue V, Nicolas V, Dormont F Pharmaceutics. 2023; 15(7).

PMID: 37513977 PMC: 10384353. DOI: 10.3390/pharmaceutics15071790.

Effect of tanshinone IIA for myocardial ischemia/reperfusion injury in animal model: preclinical evidence and possible mechanisms.

Zhu P, Shen J, Qian R, Xu J, Liu C, Hu W Front Pharmacol. 2023; 14:1165212.

PMID: 37261285 PMC: 10228700. DOI: 10.3389/fphar.2023.1165212.

References

Ovize M, Baxter G, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy D . Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res. 2010; 87(3):406-23. DOI: 10.1093/cvr/cvq129. View

Strijdom H, Genade S, Lochner A . Nitric Oxide synthase (NOS) does not contribute to simulated ischaemic preconditioning in an isolated rat cardiomyocyte model. Cardiovasc Drugs Ther. 2004; 18(2):99-112. DOI: 10.1023/B:CARD.0000029027.50796.84. View

Ferdinandy P, Szilvassy Z, Horvath L, Csont T, Csonka C, Nagy E . Loss of pacing-induced preconditioning in rat hearts: role of nitric oxide and cholesterol-enriched diet. J Mol Cell Cardiol. 1998; 29(12):3321-33. DOI: 10.1006/jmcc.1997.0557. View

Heusch G . Hibernating myocardium. Physiol Rev. 1998; 78(4):1055-85. DOI: 10.1152/physrev.1998.78.4.1055. View

Skyschally A, Gres P, Hoffmann S, Haude M, Erbel R, Schulz R . Bidirectional role of tumor necrosis factor-alpha in coronary microembolization: progressive contractile dysfunction versus delayed protection against infarction. Circ Res. 2006; 100(1):140-6. DOI: 10.1161/01.RES.0000255031.15793.86. View

Crisostomo V, Maestre J, Maynar M, Sun F, Baez-Diaz C, Uson J . Development of a closed chest model of chronic myocardial infarction in Swine: magnetic resonance imaging and pathological evaluation. ISRN Cardiol. 2013; 2013:781762. PMC: 3825272. DOI: 10.1155/2013/781762. View

Szilvassy Z, Ferdinandy P, Nagy I, JAKAB I, Koltai M . The effect of continuous versus intermittent treatment with transdermal nitroglycerin on pacing-induced preconditioning in conscious rabbits. Br J Pharmacol. 1997; 121(3):491-6. PMC: 1564716. DOI: 10.1038/sj.bjp.0701163. View

White S, Frohlich G, Sado D, Maestrini V, Fontana M, Treibel T . Remote ischemic conditioning reduces myocardial infarct size and edema in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2014; 8(1 Pt B):178-188. DOI: 10.1016/j.jcin.2014.05.015. View

Botker H, Kharbanda R, Schmidt M, Bottcher M, Kaltoft A, Terkelsen C . Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet. 2010; 375(9716):727-34. DOI: 10.1016/S0140-6736(09)62001-8. View

10.

Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S . Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet. 2013; 382(9892):597-604. DOI: 10.1016/S0140-6736(13)61450-6. View

11.

Heusch G . Nitroglycerin and delayed preconditioning in humans: yet another new mechanism for an old drug?. Circulation. 2001; 103(24):2876-8. DOI: 10.1161/01.cir.103.24.2876. View

12.

Ferdinandy P, Schulz R, Baxter G . Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev. 2007; 59(4):418-58. DOI: 10.1124/pr.107.06002. View

13.

du Pre B, van Veen T, Young M, Vos M, Doevendans P, van Laake L . Circadian rhythms in cell maturation. Physiology (Bethesda). 2014; 29(1):72-83. DOI: 10.1152/physiol.00036.2013. View

14.

Jamieson R, Friend P . Organ reperfusion and preservation. Front Biosci. 2007; 13:221-35. DOI: 10.2741/2672. View

15.

Gill R, Manouchehri N, Liu J, Lee T, Cho W, Thiesen A . Cyclosporine treatment improves cardiac function and systemic hemodynamics during resuscitation in a newborn piglet model of asphyxia: a dose-response study. Crit Care Med. 2012; 40(4):1237-44. DOI: 10.1097/CCM.0b013e3182387d2b. View

16.

Khaliulin I, Clarke S, Lin H, Parker J, Suleiman M, Halestrap A . Temperature preconditioning of isolated rat hearts--a potent cardioprotective mechanism involving a reduction in oxidative stress and inhibition of the mitochondrial permeability transition pore. J Physiol. 2007; 581(Pt 3):1147-61. PMC: 1976396. DOI: 10.1113/jphysiol.2007.130369. View

17.

Speakman J . Body size, energy metabolism and lifespan. J Exp Biol. 2005; 208(Pt 9):1717-30. DOI: 10.1242/jeb.01556. View

18.

Przyklenk K, Heusch G . Late preconditioning against myocardial stunning. Does aspirin close the "second window" of endogenous cardioprotection?. J Am Coll Cardiol. 2003; 41(7):1195-7. DOI: 10.1016/s0735-1097(03)00087-1. View

19.

Suarez-Barrientos A, Lopez-Romero P, Vivas D, Castro-Ferreira F, Nunez-Gil I, Franco E . Circadian variations of infarct size in acute myocardial infarction. Heart. 2011; 97(12):970-6. DOI: 10.1136/hrt.2010.212621. View

20.

Sabbah H, Stein P, Kono T, Gheorghiade M, Levine T, Jafri S . A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol. 1991; 260(4 Pt 2):H1379-84. DOI: 10.1152/ajpheart.1991.260.4.H1379. View